Primary B-cell mucosa-associated lymphoid tissue (MALT) lymphoma of the iris is rare. The largest published series of 14 iris lymphomas included 3 such lymphomas.1 Thus, data concerning the effectiveness of treatment of these tumors are limited. External radiotherapy (the main treatment), resection, and systemic chemotherapy can cause substantial morbidity. Rituximab monoclonal antibody, targeting CD20 on B cells, has been used systemically and intralesionally to treat orbital and primary intraocular lymphomas and ocular inflammatory diseases.2,3 To our knowledge, we report the first case of primary iris MALT lymphoma treated with intralesional rituximab injection.
Demirci H, Grant JS, Elner VM. Intralesional Rituximab for Primary Iris Lymphoma. JAMA Ophthalmol. 2015;133(1):104–105. doi:10.1001/jamaophthalmol.2014.3303
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: